Tilray Brands
Global cannabis and consumer goods company. Largest cannabis company by revenue globally with operations in 20+ countries.
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Tilray Brands earns a Neutral rating at a 42.3 composite score and 2/5 conviction. Regulatory is the leading pillar at 62.0, supported by an 80.0 jurisdiction score for Canada and an 80.0 enforcement score, with no enforcement hits recorded. Fundamentals contribute a middling 53.0, reflecting stronger market-cap and cash-runway subscores against weak growth and profitability. Editorial registers 30.0 amid no newsroom or brief activity, while market performance is the principal drag at 15.0, entirely reflecting the limited liquidity reading from institutional pricing feeds. The resulting profile supports neither a premium stance nor a fully bearish call.
Licensed fundamentals data show year-over-year revenue contraction of 7.8%, a gross margin near 27.7%, and an operating margin of negative 52.7%. Those readings explain the modest revenue-growth, gross-margin, and operating-margin subscores of 42.2, 46.1, and 36.4, respectively. EBITDA remained positive at roughly $17.8 million, but net income was a loss of approximately $1.34 billion. That combination preserves the stretched financial condition: positive EBITDA does not offset substantial bottom-line losses or establish durable balance-sheet strength. Primary regulatory filings show the latest filing dated June 30, 2026, with one regulatory event during the latest 90-day period and three across 180 days. The 34.4 cadence subscore remains well below the jurisdiction and enforcement components, limiting the full contribution from Tilray’s strongest pillar.
The forward catalyst sits squarely in regulatory execution. Canada’s favorable 80-point jurisdiction posture and the absence of enforcement hits provide the clearest base for composite improvement, while a more active filing and event cadence can lift the weakest component inside the 62-point regulatory pillar. CIN newsroom coverage currently supplies no incremental confirmation, leaving primary regulatory filings as the decisive channel for a rating change. Fundamentals can stabilize the thesis through improved growth and margins, but the existing pillar structure assigns greater immediate influence to regulatory developments. The single most important signal to watch is an acceleration in constructive regulatory-event cadence without any enforcement hits.
- IR / PR agency
- Prosek Partners
- IR email
- investors@tilray.com
- IR page
- Investor relations
- Headquarters
- 655 MADISON AVENUE, 19TH FLOOR, NEW YORK, NY, 10065
- Phone
- 519.322.8800
- CEO
- Irwin D. Simon
- CFO
- Carl Merton
- SEC CIK
- 1731348
- Website
- Company website
- Market cap
- $545.7M
- Enterprise value
- $641.6M
- Price to book
- 0.35
- Price to sales
- 0.64
- EV / EBITDA
- -4.84
- Revenue (TTM)
- $858.3M
- Gross profit (TTM)
- $237.6M
- EBITDA
- $17.8M
- Operating margin
- -52.7%
- Profit margin
- -156.7%
- Rev growth YoY
- -7.8%
- Return on equity
- -63.2%
- Return on assets
- -1.5%
- EPS (TTM)
- $-14.63
- EPS est. current year
- $-0.11
- Wall St. target price
- $9.55
- Shares outstanding
- 123.5M
- Insider ownership
- 0.7%
- Institutional ownership
- 9.4%
- Beta
- 1.90
- Full-time employees
- 2,842
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Annual report
- Latest 10-K
- Proxy statement
- Latest DEF 14A
- Filing portal
- SEDAR+
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for Tilray Brands (TLRY)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Tilray Brands (TLRY), a cannabis-sector equity listed on NASDAQ in the Canadian LP category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
Analyst average price target $7.24.
CIN editorial stance: Event-Driven Opportunity. Setup improving. Analyst upside 81% detected. (5 bullish signals, 3 bearish signals.)
Global cannabis and consumer goods company. Largest cannabis company by revenue globally with operations in 20+ countries.
Latest price: $3.99 (+1.27%) on NASDAQ.
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for TLRY are maintained by Cannabis Investor News and refreshed throughout the trading day.